2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 13, 2010, Pages 3941-3945

  Carter, David S ^a   Cai, Hai Ying ^a   Lee, Eun Kyung ^a   Iyer, Pravin S ^a   Lucas, Matthew C ^a   Roetz, Ralf ^a   Schoenfeld, Ryan C ^a   Weikert, Robert J ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Depression; Dopamine; Norepinephrine; Reuptake inhibitors; Serotonin; Triple reuptake inhibitors

Indexed keywords

2 METHOXYMETHYLPIPERAZINE; 2 PHENYLPIPERAZINE; 4 AMINOPIPERIDINE; 4 PYRANYLPIPERAZINE; 7 AZA INDOLE; ACETYL PIPERAZINE; BENZYLPIPERAZINE; BUTYLPIPERAZINE; CHLOROINDOLE; DIIMINOQUINONE; FLUOROINDOLE; ISOBUTYLPIPERAZINE; METHOXYINDOLE; METHYLCYCLOHEXYL PIPERAZINE; PHENETHYLPIPERAZINE; PIPERAZINE; PROPYLPIPERAZINE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CELL STRAIN HEK293; CHEMICAL STRUCTURE; DEPRESSION; DRUG EFFICACY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; SYNTHESIS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PIPERAZINES; SEROTONIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPSES;

EID: 77954313975     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.008     Document Type: Article

References (50)

1. M.E. Thase J. Clin. Psychiatry 61 2006 17
2. R.C. Keesler, P. Berglung, O. Demler, R. Jin, D. Loretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang J. Am. Med. Assoc. 289 2003 3095
3. W.F. Stewart, J.A. Ricci, E. Chee, and S.R. Hahn J. Am. Med. Assoc. 289 2003 3135
4. J.A. Blumenthal, A. Sherwood, S.D. Rogers, M.A. babyak, P.M. Doraiswamy, L. Watkins, B.M. Hoffman, C. O'Connell, J.J. Johnson, S.M. Patidar, R. Waugh, and A. Hinderlitter Clin. Trials 4 2007 548
5. S. Moussavi, E.M. Chatterji, A. Tandon, V. Patel, and B. Ustun Lancet 370 2007 851
6. E.E. Munce, S.A. Stansfeld, E.R. Blackmore, and D.E. Stewart J. Occup. Environ. Med. 49 2007 1206
7. B.E. Leonard Neurochem. Int. 4 339 1982 5
8. M. Fava J. Clin. Psychiatry 64 2003 26
9. D.J. Nutt J. Clin. Psychiatry 64 2007 3
10. C.J. Harmer, Z. Bhagwagar, B.A. Völlm, P.J. Cowen, and G.M. Goodwin Neuropsycopharmacology 28 2003 148
11. E. Dremencov, M. el Mansari, and P. Blier Curr. Drug Targets 10 2009 1061
12. T. Esch, and G.B. Stefano Neuroendocrinol. Lett. 25 2004 235
13. J.G. Modell, C.R. Katholi, J.D. Modell, and R.L. DePalma J. Clin. Pharm. Ther. 61 1997 478
14. N. Sussman J. Clin. Psychiatry 64 2003 19
15. P. Skolnick, P. Kreiter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa CNS Drug Rev. 12 2006 123
16. L. Azford, J.R. Boot, T.M. Hotten, M. Keenan, F.M. Martin, S. Milutinovic, N.A. Moore, M.F. Oneil, F.M. Pullar, D.F. Tupper, K. Van Belle, and V. Vivien Bioorg. Med. Chem. Lett. 13 2003 3277
17. Z. Chen, and P. Skolnick Expert Opin. Invest. Drugs 16 2007 1365
18. M. Fava, A.J. Rush, M. Thase, A. Clayton, S.M. Stahl, J.F. Pradko, and J.A. Johnston J. Clin. Psychiatry 7 2005 106
19. C. Debattista, H.B. Solvanson, J. Poirier, E. Kendrick, and A.F. Schatzberg J. Clin. Psychopharmacol. 23 2003 27
20. L.H. Kumar Am. J. Geriatr. Psychiatry 9 2001 298
21. A.L. Stoll, S.S. Pillay, L. Diamond, S.B. Workum, and J.O. Cole J. Clin. Psychiatry 57 1996 72
22. M.C. Lucas, D.S. Carter, H. Cai, E.K. Lee, R.C. Schoenfeld, S.S. Steiner, Marzia. Villa, V. Weikert, R.J. Weikert, and P. Iyer Bioorg. Med. Chem. Lett. 19 2009 4630
23. 3H]-Vanoxerine, respectively. The specific details of this assay are reported in Carter, D. S.; Schoenfeld, R. C.; Weikert, R. J. WO 2008019971.
24. MW = 305, Clog P = 3.68, PSA = 27.
25. D.E. Clark Drug Discovery Today 8 2003 927
26. J.H. Meyer, V.S. Goulding, A.A. Wilson, D. Hussey, B.K. Christensen, and S. Houle Psychopharmacology 162 2002 102
27. X. Liu, O. Vilenski, J. Kwan, S. Apparsundaram, and R. Weikert Drug Metab. Dispos. 37 2009 1548
28. i's >7.0) similar to DOV-216,303 and SERT selective based in buproprion augmentation trials.
29. T. Yamamoto, M. Nishiyama, and Y. Koie Tetrahedron Lett. 39 1998 2367
30. M. Prashad, X.Y. mak, Y. Liu, and O. Repi J. Org. Chem. 68 2003 1163
31. S. Dubbaka Synlett 2005 709
32. 3) δ 7.47 (d, J = 9.0 Hz, 1H), 7.27-7.17 (m, 4H), 7.13-7.07 (m, 2H), 7.16 (d, J = 3.1 Hz, 1H), 6.96 (dd, J = 9.0, 2.4 Hz, 1H), 6.56 (dd, J = 3.1, 0.8 Hz, 1H), 3.85-3.77 (m, 1H), 3.65-3.75 (br s, overlapping, 1H), 3.30-3.10 (m, 5H) 2.80-2.60 (br s, overlapping, 1H), 2.64-2.56 (m, 1H), 1.51 (br s, 9H), 0.93 (s, 9H), 0.63 (s, 3H), 0.60 (s, 3H).
33. Iyer, P.; Lucas, M. C.; Schoenfeld, R. C.; Villa, M.; Weikert, R. J. US 2007123527.
34. Clearance measured in HT format: total incubation volume 250 μL, 0.5 mg/mL human microsomal protein, reaction started by adding NADPH and performed at 37 °C with no shaking. 40 μL aliquots at four time points (0.1, 10, 20 and 30 min) were taken then the samples were transferred to 384 well plates for LC/MS analysis
35. Clearance measured in human liver microsomes (μL/min/mg): low stability >35, medium stability 35-6, high stability <6.5.
36. J.M. Groot, F. Wakenhut, G. Whitlock, and R. Hyland Drug Discovery Today 14 2009 964
37. The piperazine starting material (1-Boc-3-phenyl piperazine) for compound 17 was commercially available.
38. M. Berkheij, L. van der Sluis, C. Sewing, D.J. den Boer, J.W. Terpstra, H. Hiemstra, W.I.I. Bakker, A. van den Hoogenband, and J.H. van Maarseveen Tetrahedron Lett. 2005 2369
39. CYP2D6 inhibition was measured in a fluorescence based assay where CYP marker substrates become fluorescent upon CYP metabolism.
40. (R)-2-Propylpiperazine and (S)-2-propylpiperazine were prepared from (R)-N-Boc-norvaline and (S)-N-Boc-norvaline, respectively by the method described in the following patent
41. WO 03082877 A1
42. (a) (R)-2-Propylpiperazine and (S)-2-propylpiperazine were prepared from (R)-N-Boc-norvaline and (S)-N-Boc-norvaline, respectively by the method described in the following patent; (b) WO 03082877 A1; (c) Both piperazines were Boc-protected and converted to the final compounds (S)-19 and (R)-19 by the method outlined in Scheme 1.
43. 1/2 = 0.8 h, AUC = 182 ng-h/mL.
44. The absolute configurations of (S)-19 and (R)-19 were tentatively assigned based on comparing data from (S)-19 and (R)-19.
45. Super critical fluid chromatography: B. Banu, K. Bharathi, and G.M. Babu J. Pharm. Res. 2 2009 148
46. S. Zhou, S.Y. Chan, B.C. Goh, E. Chan, W. Duan, M. Huang, and H.L. Mcleod Clin. Pharmacokinet. 44 2005 279
47. A.S. Kalgutkar, and J.R. Soglia Exp. Opin. Drug Metab. Toxicol. 1 2005 91
48. obs) and the data is plotted as a % of control (no inhibitor). In this manuscript 3A4 TDI is reported as a % of t = 12 min. Compounds with a greater rate of inactivation than verapamyl are categorized as high, while compounds with a rate less than ethynylestradiol are categorized as low.
49. J. Rawal, R. Jones, A. Payne, and I. Gardner Xenobiotica 38 2008 1219
50. Iyer, P.; Lin, C.; Lucas, M.; Lynch, S.; Madera, A. M.; Ozboya, K.; Schoenfeld, R.; Weikert, R. WO 2009153178.